IMP 9064
Alternative Names: IMP-9064Latest Information Update: 05 Dec 2023
At a glance
- Originator IMPACT Therapeutics
- Class Antineoplastics
- Mechanism of Action Ataxia telangiectasia mutated protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 20 Oct 2023 Efficacy, adverse event and pharmacokinetics data from a phase I/II trial presented at the 48th European Society for Medical Oncology Congress 2023 (ESMO-2023) .
- 13 Oct 2023 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy) in Australia, Taiwan, China (PO) (NCT05269316)
- 13 Oct 2023 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Monotherapy) in Australia, China, Taiwan (PO) (NCT05269316)